NAD+ (nicotinamide adenine dinucleotide) is among the most studied molecules in the longevity science literature of the past decade — and for good reason. It is a cofactor in hundreds of enzymatic reactions central to energy metabolism, DNA repair, and gene expression regulation. Its tissue concentrations measurably and consistently decline with age across both rodent and human studies. And precursors that can restore NAD+ levels — particularly NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — are now the subject of multiple human clinical trials, with results that are intriguing but more nuanced than the supplement marketing suggests.
The enthusiasm for NAD precursors is scientifically grounded: David Sinclair's work at Harvard demonstrated that restoring NAD levels in old mice produced dramatic improvements in muscle function, endurance, and mitochondrial health. Johan Auwerx's work in Lausanne showed NR supplementation activated mitochondrial biogenesis and improved metabolic function. The human translation has been more complicated — raising blood NAD metabolites in human trials is achievable, but demonstrating downstream functional benefits has proven more difficult. The most compelling human evidence remains Yoshino 2021 in Science: NMN 250mg/day improved insulin-stimulated glucose disposal in skeletal muscle of postmenopausal women by 25% in a small but rigorous RCT. This is not nothing — but it is also not the comprehensive anti-aging effect the most enthusiastic coverage suggested.
| Feature | NMN | NR (Nicotinamide Riboside) |
|---|---|---|
| Molecular weight | 334 g/mol | 255 g/mol (lower = more moles per gram) |
| Entry pathway | Slc12a8 transporter (debated in humans); may be cleaved to NR extracellularly first | Absorbed directly; converted to NMN intracellularly |
| Oral bioavailability | Moderate; sublingual form improves absorption | Good; well-studied oral form |
| Human trial evidence | Yoshino 2021 (insulin sensitivity); Igarashi 2022 (Japan, blood NAD); multiple smaller studies | Brenner 2023; Elhassan 2019; Martens 2018; most extensive human safety database |
| Cost per 500mg dose | $0.50–$1.50 (fallen significantly 2022–2025) | $0.80–$2.00 for branded NR (Tru Niagen) |
| Safety | No serious adverse events in human trials to date; long-term data limited | Extensive safety record; Tru Niagen has GRAS status and longest-running trials |
| Best evidence for | Metabolic/insulin sensitivity in specific populations | Blood NAD raising; safety; muscle NAD in older adults |
What human trials consistently show: Both NMN and NR reliably raise blood NAD metabolites in a dose-dependent fashion; this is the most consistent finding across trials; doses of 250–500mg NMN or 300–1000mg NR produce 1.5–3× increases in blood NAD metabolites within 2–4 weeks.
What is inconsistently shown: Functional improvements — energy, cognition, muscle performance, body composition, lifespan extension — are inconsistent across human trials; Yoshino 2021 showed insulin sensitivity improvement in a specific population; Brenner 2023 did not show functional improvements; Martens 2018 showed improved walking speed in older adults on NR but was underpowered; the field awaits larger RCTs with longer duration and functional endpoints.
The tissue problem: Blood NAD metabolites rising does not necessarily mean muscle, brain, or liver NAD is rising proportionally; different tissues have different NMN/NR transporters and different rates of NAD utilization; Yoshino 2021 specifically measured skeletal muscle response (biopsied) not just blood — which is why that study is more convincing than blood-only biomarker trials.
The cancer concern (unresolved): NAD is required not only for sirtuin-mediated DNA repair but also for rapid tumor cell proliferation; several oncologists have raised the theoretical concern that NAD supplementation could fuel pre-existing cancer cell growth; this has not been demonstrated in human trials and remains theoretical; it is a reason for caution rather than alarm, and an active research question.
NMN: 250–500mg/day. Morning (NAD+ is higher in the morning due to circadian rhythm — NAMPT activity peaks in early day); sublingual form for better bioavailability or capsule taken with a small amount of fat; 250mg (Yoshino 2021 dose) appears sufficient in trials; some protocols use 500mg for faster NAD repletion; no clear dose-response evidence beyond 500mg in humans.
NR: 300–600mg/day. The most safety-tested option; Tru Niagen (ChromaDex brand) has the longest human safety database; generic NR supplements have proliferated and quality varies — look for COA confirming NR content and absence of niacin contamination (which would confound the dose).
Synergistic stack: TMG (trimethylglycine / betaine) 500–1000mg/day alongside NMN: NMN supplementation may consume methyl groups (methylation of nicotinamide produces MeNAM, consuming SAM-e); TMG provides methyl groups, potentially preventing depletion and improving NMN efficacy; this combination is common in longevity protocols (Sinclair uses NMN + TMG); evidence specific to this combination in humans is very limited.
Resveratrol as sirtuin activator: Resveratrol is a purported SIRT1 activator (though this mechanism is contested); Sinclair's mouse studies combined resveratrol with NMN; human data on resveratrol is inconsistent; if including: 250–500mg with a fat-containing meal (poor oral bioavailability in isolation — micronized or liposomal form preferred).
Safety and timeline: Both NMN and NR are well-tolerated in human trials at studied doses; no serious adverse events reported in trials to date; long-term data beyond 12 months is limited; most people report subjective energy improvements within 2–4 weeks (partly placebo, partly real); measure fasting glucose and basic metabolic panel at baseline and 3 months if combining with other interventions.
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.